Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-25-040225
Filing Date
2025-04-28
Accepted
2025-04-28 16:20:12
Documents
18
Period of Report
2025-06-12

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm252541-4_def14a.htm   iXBRL DEF 14A 403166
4 GRAPHIC lg_nuvectispharma-4clr.jpg GRAPHIC 10226
5 GRAPHIC px_25nuvectisproxy1pg1-bw.jpg GRAPHIC 210022
6 GRAPHIC px_25nuvectisproxy1pg2-bw.jpg GRAPHIC 171786
7 GRAPHIC sg_michaelcarson-bw.jpg GRAPHIC 17169
8 GRAPHIC sg_ronbentsur-bw.jpg GRAPHIC 6671
  Complete submission text file 0001104659-25-040225.txt   1713552

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA tmb-20241231.xsd EX-101.SCH 9016
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE tmb-20241231_lab.xml EX-101.LAB 33737
20 EXTRACTED XBRL INSTANCE DOCUMENT tm252541-4_def14a_htm.xml XML 4469
Mailing Address 1 BRIDGE PLAZA, SUITE 275 FORT LEE NJ 07024
Business Address 1 BRIDGE PLAZA, SUITE 275 FORT LEE NJ 07024 360-837-7232
Nuvectis Pharma, Inc. (Filer) CIK: 0001875558 (see all company filings)

EIN.: 862405608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-41264 | Film No.: 25880670
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)